Genome Editing Market Trends

Growth Drivers

• Innovation in manufacturing and supply chain: The existence of automated CRISPR assembly lines has successfully reduced per-unit expenses by 30%, thus suitable for the market upliftment. However, the dependency on imported viral vectors by the U.S. has risen to 58% as of 2023, which has exposed risks in supply chain facilities. Besides, the aspect of in-house manufacturing is emerging to become a competitive edge, based on which Thermo Fisher’s latest gene therapy plants are positively impacting opportunities for the market to expand globally.
• Shifts in investments and international investments: The presence of regulatory harmonization is escalating the genome editing market growth. For instance, the EU’s reviewed ATMP Regulation has streamlined gene therapy acceptances. Meanwhile, the NMPA in China is hastily accepting therapies, with 4 greenlit as of 2024. Besides, there is a huge surge in investor interest, based on which VC funding has hit USD 5.2 billion for gene editing as of 2023, thereby extremely prolific for the overall market growth.

Revenue Opportunities for Genome Editing Manufacturers (2023-2025)

Feasibility Models for Market Expansion (2022-2024)

Challenges

• Fragmentation in regulation: Diverted international administrations and regulations tend to delay market entry, creating a negative impact on the genome editing market expansion. For instance, Editas Medicine’s EDIT-101, which is suitable for Leber congenital amaurosis, experienced a delay of a year in Asia, despite the U.S. acceptance. Meanwhile, the NMPA in China has escalated reviews, but it still lags Western-based agencies. Besides, organizations, such as CRISPR Therapeutics, currently operate on parallel international clinical trials, with the aim to synchronize approvals, thus suitable for the market upliftment across different nations.
• Barriers in patient cost-effectiveness: The existence of high expenses excludes the majority of patients in low and middle-income regions, which has caused a hindrance in the market growth. For instance, out-of-pocket expenditure for gene therapies in Brazil has exceeded 5.5 times the usual yearly income. Besides, Intellia Therapeutics entered into a partnership with generic firms in India to reduce expenses by at least 45%, but the aspect of scaling is still evident and is challenging to overcome, thus negatively impacting the overall market.